Different doses of enoxaparin in the prevention of postoperative abdominal adhesions. Experimental study.

Ann Med Surg (Lond)

Research Unit, Facultad Mexicana de Medicina, Universidad La Salle, Mexico.

Published: January 2022

Background: Postoperative abdominal adhesions (PAAs) are present in more than 90% of patients undergoing abdominal surgery. They are a cause of chronic pain, hospitalizations, multiple surgeries, and infertility in women of reproductive age. The participation of three processes have been recognized: coagulation, fibrinolysis, and inflammation. The usefulness of subcutaneous enoxaparin in their prevention has been established. The objective is to establish the safest and most efficient dose for PAA prevention by testing five different doses of subcutaneous enoxaparin (0.25, 0.5, 1, 1.5, and 2 mg/kg/day) given in one dose/day for seven days.

Material And Methods: Fifty Sprague-Dawley rats were studied, 10 in each group. Adhesions were induced through controlled rubbing of the cecum and suturing of an incision in the terminal ileum. Two independent observers recorded the degree of adhesion formation at 14 days and histologically studied the adhesions.

Statistical Analysis: ANOVA compared group averages. The nonparametric Kruskal-Wallis test was used to identify group differences.

Results: The 0.5 mg/kg/day group had greater formation of adhesions (p < 0.001). There was no significant difference between the 1.5 and 2 mg/kg/day groups, though the latter group had an incidence of 27.2% of bleeding in the abdominal cavity. The degree of adhesions in the histological sections coincided with the macroscopic findings. The interobserver agreement was kappa = 0.88 (very good).

Conclusion: The safe and effective dose of subcutaneous enoxaparin to prevent PAA formation was 0.5-1.5 mg/kg/day for seven days.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666521PMC
http://dx.doi.org/10.1016/j.amsu.2021.103132DOI Listing

Publication Analysis

Top Keywords

enoxaparin prevention
8
postoperative abdominal
8
abdominal adhesions
8
subcutaneous enoxaparin
8
doses enoxaparin
4
prevention postoperative
4
adhesions
4
adhesions experimental
4
experimental study
4
study background
4

Similar Publications

Efficacy and safety of rivaroxaban in preventing venous thromboembolism in postoperative patients with gynecological malignancies: protocol for a randomised controlled open-label trial (G-alfalfa trial).

BMJ Open

December 2024

Department of Pharmacy, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetric & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China

Introduction: Compared with the guideline-recommended use of low-molecular weight heparin (LMWH) for 28 days to prevent venous thromboembolism (VTE) after cytoreductive surgery, oral rivaroxaban avoids the pain and inconvenience of daily injections and reduces medical expenses. The proposed randomised controlled trial (RCT) aims to compare the efficacy and safety of rivaroxaban and enoxaparin in preventing VTE in patients after surgery for gynaecological malignancies and to provide a reference for clinical medication prevention.

Methods And Analysis: This is a single-centre, randomised, controlled, open-label and assessor-blind clinical trial.

View Article and Find Full Text PDF

Background: Cardiac surgery patients are at increased risk for venous thromboembolism (VTE). Prevention is the most critical strategy to reduce VTE-associated morbidity and death. However, there is a lack of data on the optimal approach to VTE prophylaxis in this population of high-risk patients.

View Article and Find Full Text PDF

Background/aim: Low molecular weight heparin (LMWH) is widely employed to prevent postoperative venous thromboembolism (VTE). This study aimed at analyzing LMWH use and evaluating its efficacy and safety in immediate implant-based post-mastectomy breast reconstruction.

Patients And Methods: A monocentric retrospective analysis was conducted on patients who underwent immediate implant-based breast reconstruction (IBR) from January 2021 to December 2023.

View Article and Find Full Text PDF

Efficacy of Aspirin in Preventing Venous Thromboembolism in Total Knee and Hip Joint Replacement.

Cureus

November 2024

Orthopedics and Traumatology, Instituto de Seguridad y Servicios Sociales para los Trabajadores del Estado, Puebla, MEX.

Background: Venous thromboembolism (VTE) is a significant complication following total knee arthroplasty (TKA) and total hip arthroplasty (THA). Aspirin has gained attention as a cost-effective, safe alternative to traditional anticoagulants like enoxaparin, but comparative data on efficacy and safety remain limited.

Methods: This randomized controlled trial compared the efficacy of aspirin and enoxaparin in preventing VTE following TKA and THA.

View Article and Find Full Text PDF

Background: Venous thromboembolism (VTE) poses a major risk after abdominal contouring surgery, impacting morbidity and mortality. Despite various preventative strategies, surgeons are cautious about using enoxaparin for extended postoperative periods. This study aims to determine if a 7-day postoperative course of enoxaparin increases bleeding risks compared with a single dose of intraoperative unfractionated heparin in patients undergoing abdominal contouring surgery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!